Drugs / RTX-GRT7039
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05449132 | Sep 2022 → Aug 2024 | osteoarthritis, knee | Grünenthal GmbH | Completed | No outcome recorded |
| Phase 3 | NCT05377489 | Sep 2022 → May 2025 | osteoarthritis | Grünenthal GmbH | Completed | No outcome recorded |
| Phase 3 | NCT05248386 | Aug 2022 → Nov 2024 | osteoarthritis | Grünenthal GmbH | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RTX-GRT7039 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05377489 ↗ |
| Route | Other | “RTX-GRT7039 monoarticular injections or bilateral intra-articular injections.” NCT05377489 ↗ |